European Commission moves to centralize HTA

The European Commission issued a proposal on Tuesday that aims to promote cooperation among Health Technology Assessment bodies for the clinical assessment of new drugs and devices in an effort to remove duplication and discrepancies in evaluating the clinical benefits of a product.

Due to differing national and regional methodologies for HTA across Europe, market access for innovative technologies is "impeded and distorted" and contributes to a lack of business predictability, higher costs for industry, delays in access to technologies, duplication of work and inefficient use of resources, according to the EC...